The Biodistribution and Utility of 99m Tc-Ethylenedicysteine-Deoxyglucose ( 99m Tc-Glucosamine) in the Identification of Active Disease in Patients with Rheumatoid Arthritis—a Single Center Prospective Study
The Biodistribution and Utility of 99m Tc-Ethylenedicysteine-Deoxyglucose ( 99m Tc-Glucosamine) in the Identification of Active Disease in Patients with Rheumatoid Arthritis—a Single Center Prospective Study
Osayande Evbuomwan(Nuclear Medicine Department, University of The Free State, Universitas Academic Hospital, Lower Ground Floor, Logeman Street, Bloemfontein 9301, South Africa); Barend Jansen Van Rensburg(University of The Free State, Bloemfontein, South Africa); Gerrit Engelbrecht(Nuclear Medicine Department, University of The Free State, Universitas Academic Hospital, Lower Ground Floor, Logeman Street, Bloemfontein 9301, South Africa); Cathryn H. S. Driver(Department of Radiochemistry, South African Nuclear Energy Corporation, Pretoria, South Africa); Mathys Labuschagne(University of The Free State, Bloemfontein, South Africa); Joseph Sempa(University of The Free State, Bloemfontein, South Africa); Je’nine Horn‑Lodewyk(Central University of Technology, Bloemfontein, South Africa)
58권 2호, 52~61쪽
초록
Purpose Our objectives were to investigate the utility of 99mTc-ethylenedicysteine-deoxyglucose (ECDG) in identifying active diseasein the joints of patients with rheumatoid arthritis (RA), as well as to evaluate the biodistribution of this radiopharmaceutical. Methods A prospective study was conducted at the Department of Nuclear Medicine of the University of the Free State/Universitas Academic Hospital in Bloemfontein, South Africa. Twenty-two participants from the rheumatology departmentdiagnosed with RA according to the ACR/EULAR classification criteria were enrolled. Participants were injected with20–25 mCi of 99mTc-ECDG. Flow, blood pool, whole body, delayed static, and SPECT/CT images were acquired. Knownsites of disease were qualitatively assessed for intensity of uptake, and disease severity was graded (Grade 0–3). Results Twenty-two participants were studied. The median (interquartile range) age was 59 (49–68) years, and the majority(n = 21; 95.5%) were females. There was abnormal increased uptake of 99mTc-ECDG noted in majority of the sites of knowndisease, including unknown sites. SPECT/CT imaging localized radiotracer uptake specifically to the synovial space. Similarbiodistribution of radiotracer was noted in all patients, irrespective of disease severity or fasting status. Conclusion 99mTc-ECDG can efficiently assess disease activity in the joints of patients with RA. It accumulates in sites of bothclinical and subclinical disease and might be a very useful tool for the rheumatologist in the management of patients with RA.
Abstract
Purpose Our objectives were to investigate the utility of 99mTc-ethylenedicysteine-deoxyglucose (ECDG) in identifying active diseasein the joints of patients with rheumatoid arthritis (RA), as well as to evaluate the biodistribution of this radiopharmaceutical. Methods A prospective study was conducted at the Department of Nuclear Medicine of the University of the Free State/Universitas Academic Hospital in Bloemfontein, South Africa. Twenty-two participants from the rheumatology departmentdiagnosed with RA according to the ACR/EULAR classification criteria were enrolled. Participants were injected with20–25 mCi of 99mTc-ECDG. Flow, blood pool, whole body, delayed static, and SPECT/CT images were acquired. Knownsites of disease were qualitatively assessed for intensity of uptake, and disease severity was graded (Grade 0–3). Results Twenty-two participants were studied. The median (interquartile range) age was 59 (49–68) years, and the majority(n = 21; 95.5%) were females. There was abnormal increased uptake of 99mTc-ECDG noted in majority of the sites of knowndisease, including unknown sites. SPECT/CT imaging localized radiotracer uptake specifically to the synovial space. Similarbiodistribution of radiotracer was noted in all patients, irrespective of disease severity or fasting status. Conclusion 99mTc-ECDG can efficiently assess disease activity in the joints of patients with RA. It accumulates in sites of bothclinical and subclinical disease and might be a very useful tool for the rheumatologist in the management of patients with RA.
- 발행기관:
- 대한핵의학회
- 분류:
- 핵의학